Slide 1: Vimta Labs Limited Investor Presentation Q4 & FY25
Vimta Labs Limited Investor Presentation Q4 & FY25
Slide 2: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 3: Table of Contents
Q4 & FY25 Earnings Company Overview Table of Contents Industry Landscape Our Competitive Advantage Way Forward
Slide 4: Q4 & FY25 Earnings
Q4 & FY25 Earnings Q4 & FY25 Highlights FY25 Business Updates Key Metrics: Q4 & FY25 Profit & Loss Statement Financial Track Record Shareholding Pattern
Slide 5: Q4 FY25 Highlights
Q4 FY25 Highlights Rs 961 Mn Rs 347 Mn Rs 250 Mn Margin 36.1% Total Income EBITDA PBT ₹ Rs 8.22 Rs 39 Mn Rs 183 Mn Margin 19.1% EPS CAPEX Outflow PAT 5
Slide 6: FY25 Highlights
FY25 Highlights Rs 3,482 Mn Rs 1262 Mn Rs 890 Mn Margin 36.2% Total Income EBITDA PBT Rs 30.02 Rs 668 Mn ₹ Rs 791 Mn Margin 19.2% EPS CAPEX Outflow PAT 0.02x Rs 85 Mn Rs 329 Mn (March 31st 2025) (March 31st 2025) Debt to Equity Ratio Total Debt Cash and Cash Equivalents 6
Slide 7: FY25 Business Updates
FY25 Business Updates Successful regulatory audits from various regulatory authorities: USFDA (Clinical GLP); European Medicines Agency (cGMP – human health and animal health); Turkey (cGMP); Kazakhastan (GCP), NGCMA (OECD-GLP) and CDSCO (GCP, Medical Devices). Forayed into Clinical trial servic
Slide 8: Key Metrics: Q4 FY25
Key Metrics: Q4 FY25 Total Income EBIDTA & EBIDTA PAT & PAT Margin Basic EPS (In ₹ Mn) Margin (In ₹ Mn, %) (In ₹ Mn, %) (In ₹) EBIDTA EBIDTA Margin PAT PAT Margin 31.4% 31.9% 31.2% YoY YoY 200 YoY 19% 19% 175 37.6% 19% 19.2% 150 36.0% 36.1% 125 19% 19% 5 100 19% 75 19% 50 19% 19.1% 19.1% 263 343 347
Slide 9: Key Metrics: FY25
Key Metrics: FY25 Total Income EBIDTA & EBIDTA PAT & PAT Margin Basic EPS (In ₹ Mn) Margin (In ₹ Mn, %) (In ₹ Mn, %) (In ₹) EBIDTA EBIDTA Margin PAT PAT Margin 19.1% 29.1% 725 36.8% YoY YoY YoY 20% 700 675 650 19% 625 36.2% 600 33.4% 19.2% 575 19% 550 525 500 18% 475 450 425 16.7% 18% 400 375 350 32
Slide 10: Financial Track Record
Financial Track Record TOTAL INCOME (₹ Mn) PROFITABILITY (₹ Mn) EBITDA & EBITDA Margin PAT & PAT Margin 36% 19% 33% 17% 29% 31% 15% 15% 25% 18% 4% 10% 11.2% 25.1% 46.3% 1,837 2,115 2,797 3,216 2,923 3,482 330 538 817 984 977 1,262 214 413 482 488 668 CAGR CAGR 68 CAGR FY20 FY21 FY22 FY23 FY24 FY25 F
Slide 11: Profit & Loss Statement
Profit & Loss Statement Particulars (₹ Mn) Q4 FY25 Q4 FY24 YoY (%) Q3 FY25 QoQ(%) FY25 FY24 YoY (%) Revenue from Operations 944.4 727.3 899.0 3,439.8 2,886.0 Other Income 16.4 3.8 12.0 42.4 37.1 Total Income 960.8 731.2 31.4% 911.0 5.5% 3,482.2 2,923.1 19.1% Material and Testing Costs 181.6 132.9 20
Slide 12: Shareholding Pattern
Shareholding Pattern Shareholding as on 31st March 2025 Share Information as on 31st March 2025 NSE Ticker VIMTALABS BSE Ticker 524394 Market Cap (INR Cr) 2,223.67 Others % free-float 63.30% Promoters 58.2% Free-float market cap (INR Cr) 1,407.57 36.7% Total Debt (INR Mn) 85 Cash & Cash Equivalents
Slide 13: Company Overview
Company Overview Vimta at a Glance Our Journey Services Geographical Presence Management
Slide 14: Vimta at a Glance
Vimta at a Glance Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high- quality, cutting-edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics, sm
Slide 15: Our Journey
Our Journey Infrastructure People Investment Capabilities Revenue s Pharma & Biopharma: Discovery & 2024 600,000+ ft2 1300+ 492 M development services; Food; Environment; Electronics Testing 3,216 M Analytical – Pharma, Biopharma & 2015 400,000+ ft2 1000+ 580 M Food; Clinical Research; Preclinical;
Slide 16: Our offerings
Our offerings Drug Food & Agri Electronics & Environment discovery and Testing Electricals Testing & development Testing Consultancy services 16
Slide 17: Drug discovery and development services
1. Drug discovery and development services Offerings Pharma Analytical Clinical Research Preclinical Research Industry Pharmaceuticals, Biologics, Medical Pharmaceuticals, Biologics, Nutraceuticals, Medical Devices, Animal Health. Device, Agrochemical, Speciality Chemicals Accreditations & DCA, USFD
Slide 18: Food & Agri Testing
2. Food & Agri Testing Industry Food Manufacturing & Processing, Cultivation, Export, Retail, Nutraceuticals, Agro-chemicals, Water & Beverages, Animal Feed No. of Locations 7 (Hyderabad, Mumbai (NFL), Ahmedabad, Bengaluru, Nellore, Nashik, Noida) Accreditations & • FSSAI, ISO 17025, BIS, APEDA, EIS
Slide 19: Electricals & Electronics Testing & Certification
3. Electricals & Electronics Testing & Certification Industry Aviation, Defence, Medical Device, Telecom, Home appliances, Toys, Industrial & control equipment, Consumer electronics, Rail & Automotive, IT, IOT, physical security products, and allied industries No. of Laboratories 1 (Hyderabad) Accre
Slide 20: Environment Testing & Consultancy Services
4. Environment Testing & Consultancy Services Industry Manufacturing and Processing industries, Oil & Gas, Power, Cement, Mining, Infrastructure, etc. No. of Locations 4 (Hyderabad, Chennai, Kolkata and Noida) Accreditations & MoEF, ISO 17025, QCI/NABET, OSHAS 45000 Regulatory Approvals Post proje
Slide 21: Geographical Presence
Geographical Presence Hyderabad (Headquarters) Food Pharma Electronics & Electrical Environment Food Environment Electrical and Electronics Hyderabad Hyderabad Hyderabad Ahmedabad Chennai Noida Noida Mumbai (NFL) Kolkata Nashik Bengaluru Nellore 21
Slide 22: Key Management Team
Key Management Team S P Vasireddi Harita Vasireddi Sreenivas Neerukonda Siva Kambhampati Harriman Vungal Executive Chairman Managing Director Executive Director Chief Financial Officer Executive Director - Operations Dr. S P Vasireddi is a Scientist – Harita has close to 25 years of Sreenivas’s core
Slide 23: Industry Landscape
Industry Landscape Market Opportunity Factors Driving Industry Growth
Slide 24: Markets Opportunity Global
Markets Opportunity Pharmaceutical & Preclinical Food Testing Environment Testing Electronics Testing Biopharmaceuticals 957.6 127.3 40.5 20.2 13.4 (USD Bn) 76.6 Global 11.1 405.5 19.5 6.8 2020 | 2028 2023 | 2028 2022 | 2032 2022 | 2030 2021 | 2031 24
Slide 25: Markets Opportunity Indian
Markets Opportunity Pharmaceutical & Preclinical Food Testing Environment Testing Electronics Testing Biopharmaceuticals 130 0.9 0.4 13.4 1 0.6 (USD Bn) Indian 0.2 42 0.5 6.8 2021 | 2030 2021 | 2030 2022 | 2027 2021 | 2026 2021 | 2028 25
Slide 26: Factors Driving Industry Growth
Factors Driving Industry Growth Drug Food Electrical & Environment Discovery & Testing Electronics Testing Development Testing Increasing demand for Growing international Surge in demand for Increase in regulations to new drug innovations, food regulations, certification services of address the grow
Slide 27: Our Competitive Advantage
Our Competitive Advantage Our Position in the CRTO Landscape Our Strength
Slide 28: Our Position in the CRTO Landscape
Our Position in the CRTO Landscape Pharma Analytical Food Testing #1 in India #1 in India Customers – 90% of India top 20 Serving 7 of India’s top 10 food companies 36% revenues from overseas The only private EU commission approved lab in India Clinical Research Preclinical Among the most reputed CR
Slide 29: Our Strengths
Our Strengths Compliance Infrastructure Innovations Strong culture of quality and Unparalleled lab infrastructure in the Continuous addition of services and compliance country. Gold LEED certified Vivarium evolving excellence Customer Centricity Knowledge Long term partnerships Multi-disciplinary, k
Slide 30: Way Forward
Way Forward Our Key Growth Drivers & Strategies
Slide 31: Our Key Growth Drivers & Strategies
Our Key Growth Drivers & Strategies Favourable Core business Core operational Best markets strategies strategies practices Growth momentum Capacity expansions Operational excellence Good corporate in markets governance Service innovations Hiring right talent Growing demand Risk manag
Slide 32: Thank You
Thank You Vimta Labs Ltd. Siddesh Chawan Chief Financial Officer Siddesh.Chawan@in.ey.com Advait Bhadekar Siva Rama Krishna Kambhampati Advait.Bhadekar@in.ey.com Siva.Kambhampati@vimta.com Registered Office Plot NSE: VIMTALABS Plot #142, IDA Phase 2 BSE: 524394 Cherlapally, Hyderabad ISIN: INE579C01